Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors
Summary Amatuximab is a chimeric monoclonal antibody that targets mesothelin, which is expressed in virtually all mesotheliomas and pancreatic adenocarcinomas. The objective of this study was to determine the dose-limiting toxicity and the maximum tolerated dose. Patients with mesothelioma, pancreat...
Saved in:
Published in | Investigational new drugs Vol. 33; no. 2; pp. 380 - 388 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Boston
Springer US
01.04.2015
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Be the first to leave a comment!